MannKind and Rose Pharma agree to develop inhaled GLP-1 therapy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. CSX
7. LRCX
8. MRK
9. LVS
10. SAP

Go back to MannKind and Rose Pharma agree to develop inhaled GLP-1 therapy

MannKind and Rose Pharma Inc Enter Licensing and Collaboration Agreement to Develop an Inhaled Rapid-Acting, Short-Duration GLP-1 for Weight Management

September 9, 2026 6:30 AM EDT

Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKinds Technosphere® inhalation technologyMannKind to receive an equity interest and potential royalties while providing pharmaceutical development and manufacturing support through completion of a Phase 1b clinical study

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company focused on developing innovative, patient-centric therapies for chronic diseases, and Rose Pharma Inc. (Rose Pharma) today announced that they have entered into a worldwide licensing and collaboration agreement to... More